Lv1
78 积分 2024-03-12 加入
Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?
18天前
已完结
Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs
29天前
已关闭
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors
30天前
已关闭
Abstract 6268: TT125-802 is a potent and highly selective CBP/p300 bromodomain inhibitor for the treatment of castration resistant prostate cancer and haematological malignancies
30天前
已关闭
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
1个月前
已完结
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer
1个月前
已完结
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
2个月前
已完结
Session 5: Protein Degraders
2个月前
已完结
Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway
3个月前
已完结
Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway
3个月前
已完结
皖公网安备34019202002308
